The fundamental objective of prostate cancer surgery is total oncological excision, achieving complete removal of malignant tissue while preserving urinary control and erectile function whenever clinically safe. The prostate gland surrounds the urethra near the bladder outlet; removing it requires reconnecting the bladder directly to the urethra, an anastomosis technique crucial for post-operative urinary tract integrity. This operative intervention belongs to the domain of surgical uro-oncology and represents a standard curative pathway recommended in guidelines established by the European Association of Urology (EAU 2024) and the National Comprehensive Cancer Network (NCCN 2024).

Prostate cancer surgery involves several precise steps performed under general anesthesia. First, abdominal access is established via a low midline incision (open) or small port incisions (laparoscopic/robotic). The endopelvic fascia is incised, and the retropubic space (Space of Retzius) is opened. The complex of veins overlying the prostate apex is ligated. Clinicians then dissect the bladder neck away from the base of the prostate. The seminal vesicles and vas deferens are identified, mobilized, and transected. Neurovascular bundles running laterally along the prostate are carefully preserved using sharp, cold dissection without thermal energy if nerve-sparing is clinically indicated. The prostate apex is dissected free from the striated urinary sphincter, and the prostate is removed. A bilateral pelvic lymph node dissection is executed for intermediate- and high-risk disease. Finally, a urinary catheter is inserted, and a watertight vesicourethral anastomosis is constructed to join the bladder neck directly to the urethral stump.

• Curative Potential: Delivers complete surgical extirpation of localized prostate tumors, resulting in excellent long-term disease-specific survival (EAU Guidelines 2024).
• Accurate Pathological Staging: Provides definitive histological assessment of the whole organ, grading, tumor volume, surgical margins, and lymph node involvement.
• Definitive PSA Monitoring: Enables clear post-operative biochemical tracking, where undetectable serum PSA levels offer unambiguous evidence of disease clearance.
• Symptomatic Relief: Relieves lower urinary tract symptoms caused by bladder outlet obstruction secondary to prostate enlargement or localized tumor growth.

Inpatient recovery typically spans 1 to 3 days depending on the surgical approach (robot-assisted vs. open). An indwelling urinary bladder catheter remains in place for 7 to 14 days post-surgery to allow the vesicourethral anastomosis to heal. Full physical recovery and return to normal non-strenuous activities occur within 4 to 6 weeks. Urinary continence recovery progresses over 3 to 12 months with pelvic floor exercises. Erectile function restoration depends on nerve-sparing status and patient age, taking between 6 and 24 months to reach maximum baseline recovery.

Prostate cancer surgery primarily treats clinically localized adenocarcinoma of the prostate, categorized across low-, intermediate-, and high-risk classifications according to EAU and NCCN criteria. It is also indicated in select cases of locally advanced prostate cancer (stage T3a) as part of a multimodal treatment strategy, and for persistent local disease following primary radiation failure, known as salvage radical prostatectomy.

Pre-operative preparation begins weeks prior to surgery. Patients undergo comprehensive cardiac and pulmonary risk evaluation, routine blood tests, and urine culture to rule out active urinary tract infections. Discontinuation of antiplatelet agents, anticoagulants, and certain nonsteroidal anti-inflammatory drugs occurs 5 to 7 days prior, under medical supervision. Pre-operative pelvic floor muscle training (Kegel exercises) is initiated to optimize post-operative urinary continence outcomes. Patients undergo clear liquid diet protocols and standard oral bowel preparation the day before surgery, followed by fasting after midnight.

Complications associated with radical prostatectomy vary by surgical approach and patient baseline health. Immediate surgical risks include intraoperative hemorrhage, bowel injury, ureteral injury, and deep vein thrombosis or pulmonary embolism. Early post-operative risks involve urinary tract infections, wound complications, prolonged lymphatic leakage (lymphocele), and urinary urine leaks at the surgical junction. Long-term primary complications include urinary stress incontinence (affecting 5% to 20% of patients at one year) and erectile dysfunction (affecting 30% to 70% of men, depending on age, pre-operative baseline function, and nerve-sparing extent). Rare late complications include vesicourethral anastomotic stricture formation causing urinary stream weakness.

The clinical pathway for prostate cancer surgery begins with pre-operative risk stratification, imaging, and functional assessment. Following medical clearance and bowel preparation, the patient undergoes the surgical resection under general anesthesia. Post-operative care centers on early mobilization, catheter management for 7 to 14 days, and pain control. Long-term follow-up involves monitoring prostate-specific antigen (PSA) levels to confirm biochemical recurrence-free survival, alongside structured rehabilitation for urinary continence and sexual function.